WebApr 14, 2024 · Greenwich LifeSciences has a 52-week low of $6.82 and a 52-week high of $21.50. The stock’s fifty day simple moving average is $14.92 and its 200-day simple … WebApr 13, 2024 · Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Rating) VP Jaye Thompson purchased 1,000 shares of the firm’s stock in a transaction dated Tuesday, …
H.C. Wainwright Sticks to Its Buy Rating for Greenwich LifeSciences ...
WebApr 10, 2024 · Currently, the analyst consensus on Greenwich LifeSciences is a Moderate Buy with an average price target of $38.00. See Insiders’ Hot Stocks on TipRanks >> … WebOct 4, 2024 · Business Wire. Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast … somalis in tech
Does Greenwich Lifesciences Inc (GLSI) Have What it Takes to be …
WebApr 10, 2024 · A rating of 81 puts Greenwich Lifesciences Inc ( GLSI) near the top of the Healthcare sector according to InvestorsObserver . Greenwich Lifesciences Inc's score of 81 means that it ranks higher than 81% of stocks in the sector. In addition, its overall score of 57 ranks it higher than 57% of all stocks. GLSI has an Overall Score of 57. WebMar 8, 2024 · Shares of Greenwich LifeSciences ( GLSI 0.80%) were skyrocketing 48.8% higher as of 3:19 p.m. EST on Monday. The huge jump came after the company announced the hiring of Jaye Thompson as vice... WebDec 1, 2024 · STAFFORD, Texas, December 01, 2024 -- ( BUSINESS WIRE )--Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of... small businesses in fayetteville ar